IBRANCE® was the first cyclin-dependent kinase 4/6 (CDK4/6) inhibitor approved for mBC.1 ,2
IBRANCE® is indicated for the treatment of hormone receptor positive, human epidermal growth factor receptor 2-negative (HR+/HER2-), locally advanced or metastatic breast cancer (MBC) in combination with an aromatase inhibitor (AI) or in combination with fulvestrant in patients who have received prior endocrine therapy (ET). In pre-and peri-menopausal women, the ET should be combined with a leutinising hormone-releasing hormone agonist (LHRH).1
And when combined with fulvestrant, IBRANCE® offers enhanced efficacy to a wide ET resistant patient population, including 1st line and pre-menopausal patients.3
- IBRANCE® Summary of Product Characteristics.
- McCain J. P&T. 2015;40(8):511-520.
- Cristofanilli M, et al. Lancet Oncol. 2016;17(4):425-439.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
Date of preparation: March 2020